Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GAK | O14976 | 1/20 | 0.40 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.40 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11331246 | 0.76 | NR4A2 (0.50) | HTR1AADRA1DLMNAKDM4ECYP1A2 | |
| SCHEMBL21321494 | 0.73 | LMNA (0.55) | MTNR1AMTNR1BHTR1AADRA1DADRA1A | |
| SCHEMBL1695389 | 0.70 | HTR1A (0.47) | HTR1AADRA1DADRA1AADRA1BLMNA | |
| SCHEMBL1695428 | 0.68 | APP (0.64) | HTR1AADRA1DADRA1AADRA1BLMNA | |
| SCHEMBL2095741 | 0.68 | MTNR1A (0.67) | MTNR1AMTNR1BHTR1AADRA1DADRA1A | |
| SCHEMBL4081621 | 0.68 | MTNR1A (0.64) | MTNR1AMTNR1BHTR1AADRA1DADRA1A | |
| SCHEMBL7988393 | 0.68 | LMNA (0.55) | MTNR1AMTNR1BHTR1AADRA1DADRA1A | |
| SCHEMBL18544268 | 0.67 | KDM4E (0.60) | MTNR1AMTNR1BHTR1AADRA1DADRA1A | |
| SCHEMBL20614375 | 0.67 | ROCK2 (0.62) | MTNR1AMTNR1BHTR1AADRA1DADRA1A | |
| SCHEMBL18710417 | 0.67 | HTR1A (0.51) | MTNR1AMTNR1BHTR1AADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228646-A9 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF | AVIDITY BIOSCIENCES INC (US) | 2024-07-11 | — | — | US | disclosed |
| CN-111902148-B | Compositions and methods for treating muscular atrophy and tonic muscular dystrophy | 艾维迪提生物科学公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118267396-A | Nucleic acid-polypeptide compositions and uses thereof | 艾维迪提生物科学公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118265544-A | Compositions and methods for treating facial shoulder brachial muscular dystrophy | 艾维迪提生物科学公司 | 2024-06-28 | — | — | CN | disclosed |
| US-12006499-B2 | Una amidites and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-11999955-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240132611-A1 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF | Atrium Therapeutics, Inc. | 2024-04-25 | — | — | US | disclosed |
| US-20240132610-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2024-04-25 | — | — | US | disclosed |
| US-20240124600-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2024-04-18 | — | — | US | disclosed |
| CN-111655268-B | Nucleic acid-polypeptide compositions and uses thereof | 艾维迪提生物科学公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20130131155-A1 | Optimized In Vivo Delivery System with Endosomolytic Agents for Nucleic Acid Conjugates | DNA THERAPEUTICS (FR) | 2013-05-23 | — | — | US | disclosed |
| EP-2585113-A1 | OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES | DNA Therapeutics (FR) | 2013-05-01 | — | — | EP | disclosed |
| WO-2012163814-A1 | CANCER TREATMENT BY COMBINING DNA MOLECULES MIMICKING DOUBLE STRAND BREAKS WITH HYPERTHERMIA | INSTITUT CURIE (FR) | 2012-12-06 | — | — | WO | disclosed |
| WO-2011161075-A1 | OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES | DNA THERAPEUTICS (FR) | 2011-12-29 | — | — | WO | disclosed |
| WO-2008103409-A2 | COMPOSITIONS OF CHLOROQUINE COUPLED TO ANTIBODIES AND TO OTHER PROTEINS WITH METHODS FOR THEIR SYNTHESIS | KOSAK KEN M | 2008-08-28 | — | — | WO | disclosed |
| US-20080051323-A1 | Chloroquine drug compositions and methods for their synthesis | KOSAK KENNETH M | 2008-02-28 | — | — | US | disclosed |
| US-20070166281-A1 | Chloroquine coupled antibodies and other proteins with methods for their synthesis | KOSAK KENNETH M | 2007-07-19 | — | — | US | disclosed |
| WO-2007040469-A2 | CHLOROQUINE COUPLED COMPOSITIONS AND METHODS FOR THEIR SYNTHESIS | KOSAK KEN M (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070060499-A1 | Chloroquine combination drugs and methods for their synthesis | KOSAK KENNETH M | 2007-03-15 | — | — | US | disclosed |
| US-20060040879-A1 | Chloroquine coupled nucleic acids and methods for their synthesis | KOSAK KENNETH M | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124600-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | MYOF, MTPN, PYGM | MTNR1A 1141/4885MTNR1B 1102/4885HTR1A 4698/4885 |
| US-20070166281-A1 | Chloroquine coupled antibodies and other proteins with methods for their synthesis | GPR119, CLTA, CHMP4B | MTNR1A 3861/4885MTNR1B 3363/4885HTR1A 4564/4885 |
| US-20070060499-A1 | Chloroquine combination drugs and methods for their synthesis | CHMP4B, CTSA, CLTA | MTNR1A 3935/4885MTNR1B 3770/4885HTR1A 4396/4885 |
| US-20130131155-A1 | Optimized In Vivo Delivery System with Endosomolytic Agents for Nucleic Acid Conjugates | EEA1, RNASE1, ASGR1 | MTNR1A 2312/4885MTNR1B 2889/4885HTR1A 4316/4885 |
| US-20080051323-A1 | Chloroquine drug compositions and methods for their synthesis | CHMP4B, CTSA, CLTA | MTNR1A 4228/4885MTNR1B 4215/4885HTR1A 4363/4885 |
| US-20060040879-A1 | Chloroquine coupled nucleic acids and methods for their synthesis | TLR9, TLR3, EXOSC5 | MTNR1A 3730/4885MTNR1B 3959/4885HTR1A 4355/4885 |
| US-20240132611-A1 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF | TFRC, FOLR1, CD47 | MTNR1A 481/4885MTNR1B 1034/4885HTR1A 1623/4885 |
| US-20240132610-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | MYOF, MTPN, PYGM | MTNR1A 1141/4885MTNR1B 1102/4885HTR1A 4698/4885 |
| US-12006499-B2 | Una amidites and uses thereof | NCL, PNP, NASP | MTNR1A 2374/4885MTNR1B 2980/4885HTR1A 4082/4885 |
| US-20240228646-A9 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF | TFRC, FOLR1, CD47 | MTNR1A 481/4885MTNR1B 1034/4885HTR1A 1623/4885 |
| US-11999955-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | MTPN, MYOF, CPT1B | MTNR1A 1362/4885MTNR1B 1139/4885HTR1A 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.